Łukasz Galus

412 total citations
34 papers, 259 citations indexed

About

Łukasz Galus is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Łukasz Galus has authored 34 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 18 papers in Molecular Biology and 14 papers in Immunology. Recurrent topics in Łukasz Galus's work include Cancer Immunotherapy and Biomarkers (23 papers), CAR-T cell therapy research (14 papers) and Melanoma and MAPK Pathways (12 papers). Łukasz Galus is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), CAR-T cell therapy research (14 papers) and Melanoma and MAPK Pathways (12 papers). Łukasz Galus collaborates with scholars based in Poland, Hungary and United States. Łukasz Galus's co-authors include Jacek Mackiewicz, Jacek Mackiewicz, Andrzej Maćkiewicz, Tomasz Kolenda, Piotr Rutkowski, Katarzyna Tomela, Anna M. Czarnecka, Marcin Schmidt, Bożena Cybulska-Stopa and Rafał Suwiński and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Molecular Sciences.

In The Last Decade

Łukasz Galus

31 papers receiving 259 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Łukasz Galus Poland	12	141	127	91	44	25	34	259
Robert J. Van Gulick United States	9	122 0.9×	129 1.0×	68 0.7×	29 0.7×	24 1.0×	14	242
Shruti Mishra United States	9	92 0.7×	91 0.7×	187 2.1×	38 0.9×	13 0.5×	13	320
Muhammad Adnan Khattak Australia	9	185 1.3×	77 0.6×	101 1.1×	37 0.8×	21 0.8×	33	264
Yuqin Yang China	10	79 0.6×	106 0.8×	75 0.8×	47 1.1×	58 2.3×	25	270
Youwei Zhu China	8	82 0.6×	192 1.5×	48 0.5×	127 2.9×	27 1.1×	17	279
Agnes Ling Sweden	10	231 1.6×	108 0.9×	138 1.5×	55 1.3×	48 1.9×	12	350
Robin Reschke Germany	12	270 1.9×	82 0.6×	211 2.3×	16 0.4×	39 1.6×	31	390
Stephanie The United States	7	74 0.5×	71 0.6×	63 0.7×	59 1.3×	44 1.8×	15	219
Stephen K. H. Li Canada	7	94 0.7×	140 1.1×	106 1.2×	61 1.4×	19 0.8×	12	293
Maojun Di China	6	101 0.7×	240 1.9×	34 0.4×	137 3.1×	52 2.1×	16	353

Countries citing papers authored by Łukasz Galus

Since Specialization

Citations

This map shows the geographic impact of Łukasz Galus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Łukasz Galus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Łukasz Galus more than expected).

Fields of papers citing papers by Łukasz Galus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Łukasz Galus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Łukasz Galus. The network helps show where Łukasz Galus may publish in the future.

Co-authorship network of co-authors of Łukasz Galus

This figure shows the co-authorship network connecting the top 25 collaborators of Łukasz Galus. A scholar is included among the top collaborators of Łukasz Galus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Łukasz Galus. Łukasz Galus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Czarnecka, Anna M., Paweł Teterycz, Magdalena Zielińska, et al.. (2025). Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD. Targeted Oncology. 20(4). 693–705.

Tomela, Katarzyna, Luiza Handschuh, Anna Samelak-Czajka, et al.. (2025). Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy. Cancer Immunology Immunotherapy. 74(4). 110–110. 1 indexed citations

Tomela, Katarzyna, Łukasz Galus, Agnieszka Olejnik‐Schmidt, et al.. (2024). Circulating Cell-Free Microbial DNA Signatures and Plasma Soluble CD14 Level Are Associated with Clinical Outcomes of Anti-PD-1 Therapy in Advanced Melanoma Patients. International Journal of Molecular Sciences. 25(23). 12982–12982. 1 indexed citations

Galus, Łukasz, Tomasz Kolenda, Michał Michalak, & Jacek Mackiewicz. (2024). Diagnostic and prognostic role of long non-coding RNAs (lncRNAs) in metastatic melanoma patients with BRAF gene mutation receiving BRAF and MEK inhibitors. Heliyon. 10(7). e29071–e29071. 2 indexed citations

Cybulska-Stopa, Bożena, Anna M. Czarnecka, Marcin Ziętek, et al.. (2023). 1115P Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice. Annals of Oncology. 34. S672–S672. 2 indexed citations

Cybulska-Stopa, Bożena, Marcin Ziętek, Łukasz Galus, et al.. (2023). Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma. Targeted Oncology. 18(2). 235–245. 2 indexed citations

Czarnecka, Anna M., Paweł Teterycz, Łukasz Galus, et al.. (2023). 1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study. Annals of Oncology. 34. S698–S698. 1 indexed citations

Tomela, Katarzyna, Łukasz Galus, Jacek Mackiewicz, et al.. (2023). Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy. Cells. 12(5). 789–789. 13 indexed citations

Galus, Łukasz, et al.. (2023). Vitamin D supplementation increases objective response rate and prolongs progression‐free time in patients with advanced melanoma undergoing anti–PD‐1 therapy. Cancer. 129(13). 2047–2055. 24 indexed citations

10.

Galus, Łukasz, Maurycy Jankowski, Michał Nowicki, et al.. (2023). Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients. Cells. 12(6). 856–856. 2 indexed citations

11.

Cybulska-Stopa, Bożena, Łukasz Galus, Marcin Ziętek, et al.. (2023). Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment. Melanoma Research. 33(3). 208–217. 7 indexed citations

12.

Czarnecka, Anna M., Bożena Cybulska-Stopa, Marcin Ziętek, et al.. (2022). Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. Cancers. 14(9). 2123–2123. 5 indexed citations

13.

Czarnecka, Anna M., Bożena Cybulska-Stopa, Marcin Ziętek, et al.. (2022). Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. Journal of Clinical Medicine. 11(8). 2239–2239. 4 indexed citations

14.

Wróblewska, Joanna, Michał Lach, Marcin Ruciński, et al.. (2022). MiRNAs from serum-derived extracellular vesicles as biomarkers for uveal melanoma progression. Frontiers in Cell and Developmental Biology. 10. 1008901–1008901. 14 indexed citations

15.

Cybulska-Stopa, Bożena, Marcin Ziętek, Anna M. Czarnecka, et al.. (2021). Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. Journal of Dermatological Treatment. 33(4). 2168–2174. 8 indexed citations

16.

Wróblewska, Joanna, Michał Lach, Katarzyna Kulcenty, et al.. (2021). The Analysis of Inflammation-Related Proteins in a Cargo of Exosomes Derived from the Serum of Uveal Melanoma Patients Reveals Potential Biomarkers of Disease Progression. Cancers. 13(13). 3334–3334. 21 indexed citations

17.

Cybulska-Stopa, Bożena, Marcin Ziętek, Anna M. Czarnecka, et al.. (2021). Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus pembrolizumab) in treatment of patients with metastatic melanoma.. Journal of Clinical Oncology. 39(15_suppl). e21514–e21514. 2 indexed citations

18.

Cybulska-Stopa, Bożena, Renata Pacholczak‐Madej, Grażyna Kamińska‐Winciorek, et al.. (2020). First-Line Treatment of Advanced/Metastatic Melanoma with Anti-PD-1 Antibodies: Multicenter Experience in Poland. Immunotherapy. 13(4). 297–307. 10 indexed citations

19.

Cybulska-Stopa, Bożena, Anna M. Czarnecka, Iwona Ługowska, et al.. (2020). Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. Advances in Medical Sciences. 65(2). 316–323. 12 indexed citations

20.

Czerwińska, Patrycja, Jacek Mackiewicz, Urszula Kazimierczak, et al.. (2018). Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients. OncoImmunology. 7(11). e1509821–e1509821. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact